公开(公告)号：US20220119413A1

公开(公告)日：2022-04-21

申请号：US17513093

申请日：2021-10-28

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Koc-Kan Ho ,  David Diller ,  Jeffrey J. Letourneau ,  Brian F. McGuinness ,  Andrew G. Cole ,  David Rosen ,  Cornelis A. van Oeveren ,  Jason C. Pickens ,  Lin Zhi ,  Yixing Shen ,  Bijan Pedram

IPC: C07D513/04 ,  A61K31/407 ,  A61K31/4168 ,  A61K31/4353 ,  C07D235/02 ,  C07D269/02 ,  C07D277/42 ,  C07D277/60 ,  A61P29/00 ,  A61P37/00 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

公开(公告)号：US11186593B2

公开(公告)日：2021-11-30

申请号：US16735988

申请日：2020-01-07

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Koc-Kan Ho ,  David Diller ,  Jeffrey J. Letourneau ,  Brian F. McGuinness ,  Andrew G. Cole ,  David Rosen ,  Cornelis A. van Oeveren ,  Jason C. Pickens ,  Lin Zhi ,  Yixing Shen ,  Bijan Pedram

IPC: A61P11/00 ,  A61P17/00 ,  A61P35/00 ,  A61P43/00 ,  A61K31/407 ,  A61K31/4353 ,  C07D513/04 ,  A61K31/4168 ,  C07D235/02 ,  C07D269/02 ,  C07D277/42 ,  C07D277/60 ,  A61P29/00 ,  A61P37/00 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

公开(公告)号：US20200009112A1

公开(公告)日：2020-01-09

申请号：US16572493

申请日：2019-09-16

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: A61K31/40 ,  A61K31/473 ,  A61K31/138 ,  A61K31/4535 ,  A61K31/58 ,  A61K9/00 ,  A61K31/277 ,  A61K31/402 ,  A61K31/567 ,  A61K45/06

Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions.

公开(公告)号：US10441567B2

公开(公告)日：2019-10-15

申请号：US15111741

申请日：2015-01-14

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: A61K9/00 ,  A61K31/40 ,  A61K31/47 ,  A61K31/58 ,  A61K45/06 ,  A61K31/138 ,  A61K31/277 ,  A61K31/402 ,  A61K31/473 ,  A61K31/567 ,  A61K31/4535

Abstract: Provided herein are compositions and methods for the treatment of androgen and estrogen receptors mediated conditions. Specifically, a composition that includes an effective amount of a selective estrogen receptor modulator (SERM) and an effective amount of a 5a-reductase inhibitor, or a pharmaceutically acceptable salt, ester or prodrug of the foregoing is provided. Also provided are methods for the treatment of aging related conditions and diseases.

公开(公告)号：US20180298031A1

公开(公告)日：2018-10-18

申请号：US16015925

申请日：2018-06-22

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Koc-Kan Ho ,  David Diller ,  Jeffrey J. Letourneau ,  Brian F. McGuinness ,  Andrew G. Cole ,  David Rosen ,  Cornelis A. van Oeveren ,  Jason C. Pickens ,  Lin Zhi ,  Yixing Shen ,  Bijan Pedram

IPC: C07D513/04 ,  C07D277/60 ,  C07D277/42 ,  C07D269/02 ,  C07D235/02 ,  A61K31/4353 ,  A61K31/4168 ,  C07D417/12 ,  A61P37/00 ,  A61P29/00 ,  C07D471/04 ,  C07D417/14 ,  A61K31/407

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

公开(公告)号：US20180185333A1

公开(公告)日：2018-07-05

申请号：US15908504

申请日：2018-02-28

Applicant: LIGAND PHARMACEUTICALS INCORPORATED

Inventor： Keith B. Marschke ,  Lin Zhi

IPC: A61K31/4045 ,  G01N33/50 ,  A61N5/10 ,  A61K45/06 ,  A61K31/454 ,  A61K31/4155 ,  A61K31/41 ,  A61K31/4152 ,  A61K31/4015 ,  A61K31/40

Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

公开(公告)号：US10000522B2

公开(公告)日：2018-06-19

申请号：US15590813

申请日：2017-05-09

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi

IPC: C07H19/10 ,  C07H19/11

CPC classification number: C07H19/10 ,  C07H19/11

Abstract: Some embodiments of the present invention include nucleoside 5′-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.

公开(公告)号：US09492430B2

公开(公告)日：2016-11-15

申请号：US14357551

申请日：2012-11-12

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Keith Marschke ,  Virginia H. Grant ,  Steven L. Roach ,  Yixing Shen ,  Jason C. Pickens ,  Bijan Pedram ,  C. Arjan van Oeveren ,  Lino J. Valdez ,  Andrew R. Hudson

IPC: C07D403/12 ,  C07D231/46 ,  C07D405/06 ,  A61K31/404 ,  C07D209/34 ,  A61K31/41 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/454 ,  A61K45/06 ,  A61N5/10 ,  C07D401/12 ,  C12Q1/18 ,  C12Q1/66

CPC classification number: A61K31/404 ,  A61K31/41 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/454 ,  A61K45/06 ,  A61N5/10 ,  C07D209/34 ,  C07D231/46 ,  C07D231/52 ,  C07D401/12 ,  C07D403/12 ,  C07D405/06 ,  C12Q1/18 ,  C12Q1/66

Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

Abstract translation: 一些实施方案包括使用或鉴定调节粒细胞集落刺激因子受体（GCFR）的活性的化合物的组合物和方法。 一些实施方案包括使用化合物来治疗某些疾病，例如造血或神经障碍。

公开(公告)号：US08865918B2

公开(公告)日：2014-10-21

申请号：US13974937

申请日：2013-08-23

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Robert I. Higuchi ,  Cornelis Arjan Van Oeveren ,  Thomas Lot Stevens Lau

IPC: C07D295/04 ,  C07D207/12 ,  C07D209/04 ,  C07D211/22 ,  C07D215/04 ,  C07D265/36 ,  C07D295/073 ,  C07C211/52 ,  C07D207/09 ,  C07D209/12 ,  C07D207/16 ,  C07D211/60 ,  C07D207/26 ,  C07D215/18 ,  C07D207/46 ,  C07D211/56 ,  C07C255/58 ,  C07D207/08 ,  C07D209/08

CPC classification number: C07C211/52 ,  C07C205/55 ,  C07C255/58 ,  C07C2601/08 ,  C07D207/08 ,  C07D207/09 ,  C07D207/12 ,  C07D207/16 ,  C07D207/26 ,  C07D207/27 ,  C07D207/46 ,  C07D209/04 ,  C07D209/08 ,  C07D209/12 ,  C07D211/22 ,  C07D211/56 ,  C07D211/60 ,  C07D215/04 ,  C07D215/18 ,  C07D265/36 ,  C07D295/073 ,  C07F7/1804 ,  G01N2333/723

Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.

Abstract translation: 本文提供具有选自式（I），式（II），式（III），式（IV），式（V）和式（VI））的结构的化合物，其是雄激素受体调节剂和/或雄激素受体结合 代理商 还公开了制备和使用这些化合物的方法，包括但不限于使用这些化合物来处理各种条件。

公开(公告)号：US20140296292A1

公开(公告)日：2014-10-02

申请号：US14357551

申请日：2012-11-12

Applicant: Ligand Pharmaceuticals Incorporated

Inventor： Lin Zhi ,  Keith Marschke ,  Virginia H. Grant ,  Steven L. Roach ,  Yixing Shen ,  Jason C. Pickens ,  Bijan Pedram ,  C. Arjan van Oeveren ,  Lino J. Valdez ,  Andrew R. Hudson

IPC: C07D405/06 ,  C12Q1/18 ,  A61K31/454 ,  A61K31/41 ,  A61K31/4155 ,  A61N5/10 ,  A61K31/404 ,  C07D401/12 ,  C07D403/12 ,  C07D231/46 ,  C07D209/34 ,  A61K45/06 ,  C12Q1/66 ,  A61K31/4152

CPC classification number: A61K31/404 ,  A61K31/41 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/454 ,  A61K45/06 ,  A61N5/10 ,  C07D209/34 ,  C07D231/46 ,  C07D231/52 ,  C07D401/12 ,  C07D403/12 ,  C07D405/06 ,  C12Q1/18 ,  C12Q1/66

Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

Abstract translation: 一些实施方案包括使用或鉴定调节粒细胞集落刺激因子受体（GCFR）的活性的化合物的组合物和方法。 一些实施方案包括使用化合物来治疗某些疾病，例如造血或神经障碍。